ABBOTT LABORATORIES ABT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products.

On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.

Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Last close 103.70 2026-10-23
Market cap $180.63B 2026-03-31 share count
52-week range 81.97 - 132.03

Valuation FY2025 figures against the last close

P/S4.1x
P/E27.9x
P/FCF24.4x
EV/EBITDA19.5x
Dividend yield2.3%
Diluted EPS3.72

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • All Other Countries
  • Germany
  • China
  • India
  • Switzerland
  • Japan
  • United Kingdom
Revenue by geography, 8 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 17.1B (38.6%) 39% United States All Other Countries, FY2025: 16B (36.0%) 36% All Other Countries Germany, FY2025: 2.8B (6.2%) 6% Germany China, FY2025: 1.9B (4.3%) 4% China India, FY2025: 1.9B (4.2%) 4% India Switzerland, FY2025: 1.9B (4.2%) 4% Japan, FY2025: 1.5B (3.3%) United Kingdom, FY2025: 1.3B (3.0%) FY2024 United States, FY2024: 16.3B (38.9%) 39% All Other Countries, FY2024: 14.8B (35.2%) 35% Germany, FY2024: 2.5B (6.1%) 6% China, FY2024: 2.1B (5.0%) 5% India, FY2024: 1.8B (4.3%) 4% Switzerland, FY2024: 1.7B (4.2%) 4% Japan, FY2024: 1.4B (3.4%) 3% United Kingdom, FY2024: 1.2B (2.8%) FY2023 United States, FY2023: 15.5B (38.5%) 39% All Other Countries, FY2023: 14.2B (35.3%) 35% Germany, FY2023: 2.3B (5.8%) 6% China, FY2023: 2.3B (5.6%) 6% India, FY2023: 1.8B (4.4%) 4% Switzerland, FY2023: 1.6B (4.1%) 4% Japan, FY2023: 1.5B (3.8%) 4% United Kingdom, FY2023: 991M (2.5%)
Region FY2025FY2024FY2023
United States $17.13B $16.32B $15.45B
All Other Countries $15.98B $14.79B $14.17B
Germany $2.76B $2.54B $2.35B
China $1.91B $2.11B $2.25B
India $1.87B $1.82B $1.75B
Switzerland $1.87B $1.75B $1.64B
Japan $1.48B $1.44B $1.51B
United Kingdom $1.34B $1.19B $991.0M

As the company reported it, from the “Segment and Geographic Area Information - Geographic Information (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $44.33B$41.95B$40.11B$43.65B$43.08B$34.61B$31.90B$30.58B$27.39B$20.85B
Cost of revenue $19.32B$18.71B$17.98B$19.14B$18.54B$15.00B$13.23B$12.71B$12.41B$9.09B
Gross profit $25.01B$23.24B$22.13B$24.51B$24.54B$19.61B$18.67B$17.87B$14.98B$11.76B
R&D $2.94B$2.84B$2.74B$2.89B$2.74B$2.42B$2.44B$2.30B$2.26B—
SG&A $12.33B$11.70B$10.95B$11.25B$11.32B$9.70B$9.77B$9.74B$9.18B$6.74B
Total operating expenses $36.27B$35.12B$33.63B$35.29B$34.65B$29.25B$27.37B$26.93B$25.83B$17.83B
Operating income $8.05B$6.83B$6.48B$8.36B$8.43B$5.36B$4.53B$3.65B$1.56B$3.03B
Interest expense $493.0M$559.0M$637.0M$558.0M$533.0M$546.0M$670.0M$826.0M$904.0M$431.0M
Pre-tax income $8.47B$7.01B$6.66B$8.31B$8.21B$4.97B$4.08B$2.87B$2.23B$1.41B
Income tax $1.94B$6.39B$941.0M$1.37B$1.14B$497.0M$390.0M$539.0M$1.88B$350.0M
Net income $6.52B$13.40B$5.72B$6.93B$7.07B$4.50B$3.69B$2.37B$477.0M$1.40B
EPS, basic 3.737.673.283.943.972.522.071.340.270.94
EPS, diluted 3.727.643.263.913.942.502.061.330.270.94
Shares, diluted (wtd. avg.) 1.75B1.75B1.75B1.76B1.79B1.79B1.78B1.77B1.75B1.48B

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $8.52B$7.62B$6.90B$9.88B$9.80B$6.84B$3.86B$3.84B$9.41B$18.62B
Short-term investments $417.0M$351.0M$383.0M$288.0M$450.0M$310.0M$280.0M$242.0M$203.0M$155.0M
Receivables $7.93B$6.92B$6.57B$6.22B$6.49B$6.41B$5.42B$5.18B$5.25B$3.25B
Inventory $6.49B$6.19B$6.57B$6.17B$5.16B$5.01B$4.32B$3.80B$3.60B$2.43B
Total current assets $26.00B$23.66B$22.67B$25.22B$24.24B$20.44B$15.67B$14.63B$20.15B$26.78B
Property, plant and equipment $11.82B$10.66B$10.15B$9.16B$8.96B$9.03B$8.04B$7.56B$7.61B$5.71B
Goodwill $24.04B$23.11B$23.68B$22.80B$23.23B$23.74B$23.20B$23.25B$24.02B$7.68B
Other intangibles $5.53B$6.65B$8.81B$10.45B$12.74B$14.78B$17.02B$18.94B$21.47B$4.54B
Total assets $86.71B$81.41B$73.21B$74.44B$75.20B$72.55B$67.89B$67.17B$76.25B$52.67B
Short-term debt $3.03B$1.50B$1.08B$2.25B$0$7.0M$1.28B$7.0M$508.0M$3.0M
Total current liabilities $16.50B$14.16B$13.84B$15.49B$13.11B$11.91B$10.86B$9.01B$8.91B$6.66B
Long-term debt $9.90B$12.62B$13.60B$14.52B$17.30B$18.53B$16.66B$19.36B$27.21B$20.68B
Retained earnings $49.78B$47.26B$37.55B$35.26B$31.53B$27.63B$25.85B$24.56B$23.98B$25.57B
Total equity $52.13B$47.66B$38.60B$36.69B$35.80B$32.78B$31.09B$30.52B$30.90B$20.54B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $9.57B$8.56B$7.26B$9.58B$10.53B$7.90B$6.14B$6.30B$5.57B$3.20B
Depreciation and amortisation $1.43B$1.34B$1.28B$1.25B$1.49B$1.20B$1.08B$1.10B$1.05B$803.0M
Stock-based compensation $664.0M$673.0M$644.0M$685.0M$640.0M$546.0M$519.0M$477.0M$406.0M$310.0M
Capital expenditure $2.17B$2.21B$2.20B$1.78B$1.89B$2.18B$1.64B$1.39B$1.14B$1.12B
Investing cash flow -$2.42B-$2.34B-$3.13B-$1.74B-$2.01B-$2.21B-$1.81B-$1.36B-$9.62B-$248.0M
Financing cash flow -$6.31B-$5.40B-$7.09B-$7.64B-$5.49B-$2.78B-$4.29B-$10.39B-$5.28B$11.15B
Dividends paid $4.12B$3.84B$3.56B$3.31B$3.20B$2.56B$2.27B$1.97B$1.85B$1.54B
Buybacks $893.0M$1.29B$1.23B$3.79B$2.30B$403.0M$718.0M$238.0M$117.0M$522.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-010185.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 20B 40B 60B Revenue, FY2016: 20.9B Gross profit, FY2016: 11.8B Net income, FY2016: 1.4B Revenue, FY2017: 27.4B Gross profit, FY2017: 15B Net income, FY2017: 477M Revenue, FY2018: 30.6B Gross profit, FY2018: 17.9B Net income, FY2018: 2.4B Revenue, FY2019: 31.9B Gross profit, FY2019: 18.7B Net income, FY2019: 3.7B Revenue, FY2020: 34.6B Gross profit, FY2020: 19.6B Net income, FY2020: 4.5B Revenue, FY2021: 43.1B Gross profit, FY2021: 24.5B Net income, FY2021: 7.1B Revenue, FY2022: 43.7B Gross profit, FY2022: 24.5B Net income, FY2022: 6.9B Revenue, FY2023: 40.1B Gross profit, FY2023: 22.1B Net income, FY2023: 5.7B Revenue, FY2024: 42B Gross profit, FY2024: 23.2B Net income, FY2024: 13.4B Revenue, FY2025: 44.3B Gross profit, FY2025: 25B Net income, FY2025: 6.5B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $20.85B $27.39B $30.58B $31.90B $34.61B $43.08B $43.65B $40.11B $41.95B $44.33B
Gross profit $11.76B $14.98B $17.87B $18.67B $19.61B $24.54B $24.51B $22.13B $23.24B $25.01B
Net income $1.40B $477.0M $2.37B $3.69B $4.50B $7.07B $6.93B $5.72B $13.40B $6.52B

Recent filings and events

  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%
REGN REGENERON PHARMACEUTICALS, INC. $82.76B 19.4x 1.0%